Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischemic optic neuropathy

The aim of this study was to evaluate the effect of single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischemic optic neuropathy (NAION). The study includes a retrospective analysis of six eyes of six patients diagnosed with NAION. Mean time between visual loss and t...

Full description

Bibliographic Details
Main Authors: Preetam M Samant, Hemalini P Samant, Kamal A Saraiya
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Journal of Clinical Ophthalmology and Research
Subjects:
Online Access:http://www.jcor.in/article.asp?issn=2320-3897;year=2013;volume=1;issue=1;spage=27;epage=28;aulast=Samant
Description
Summary:The aim of this study was to evaluate the effect of single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischemic optic neuropathy (NAION). The study includes a retrospective analysis of six eyes of six patients diagnosed with NAION. Mean time between visual loss and the intravitreal injection was 7.8 days (range 2– 15 days). The mean age of patients was 58.2 years (range 45– 63 years). Mean visual acuity gain was two Snellen′s lines at the six-month follow-up. The mean optic nerve head peri-papillary thickness measured with spectral domain optical coherence tomography after one month decreased by an average of 230 microns. No complication related to the injection was observed during six months′ follow-up. Our case series, the fi rst of its type from the Indian subcontinent, shows that patients with acute NAION may benefi t from intravitreal ranibizumab injection.
ISSN:2320-3897